Intended for healthcare professionals
Rapid response to:
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent and legitimate interest. You may exercise your right to consent or object to a legitimate interest, based on a specific purpose below or at a partner level in the link under each purpose. These choices will be signaled to our vendors participating in the Transparency and Consent Framework. Privacy and cookie policies
List of IAB VendorsThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookies, device identifiers, or other information can be stored or accessed on your device for the purposes presented to you.
Ads can be shown to you based on the content you’re viewing, the app you’re using, your approximate location, or your device type.
A profile can be built about you and your interests to show you personalised ads that are relevant to you.
Personalised ads can be shown to you based on a profile about you.
A profile can be built about you and your interests to show you personalised content that is relevant to you.
Personalised content can be shown to you based on a profile about you.
The performance and effectiveness of ads that you see or interact with can be measured.
The performance and effectiveness of content that you see or interact with can be measured.
Market research can be used to learn more about the audiences who visit sites/apps and view ads.
Your data can be used to improve existing systems and software, and to develop new products
Your precise geolocation data can be used in support of one or more purposes. This means your location can be accurate to within several meters.
Your device can be identified based on a scan of your device's unique combination of characteristics.
Your data can be used to monitor for and prevent fraudulent activity, and ensure systems and processes work properly and securely.
Your device can receive and send information that allows you to see and interact with ads and content.
Data from offline data sources can be combined with your online activity in support of one or more purposes
Different devices can be determined as belonging to you or your household in support of one or more of purposes.
Your device might be distinguished from other devices based on information it automatically sends, such as IP address or browser type.
Allowing third-party ad tracking and third-party ad serving through Google and other vendors to occur. Please see more information on Google Ads https://policies.google.com/privacy?hl=en-US
We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data.Cookie policy
Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification List of Partners (vendors)
Rapid Response:
Underreporting Vaccine Adverse Events
Peter Collignon and his colleagues do not exaggerate the problem of
adverse
event underreporting. VAERS (Vaccine Adverse Events Reporting System) is
the voluntary system used in the U.S. to signal vaccine side effects.
During
the 18-year period from 1990 through 2007 just 88 cases of Kawasaki
Disease in children under 5 were reported to VAERS. During the same
period
about 88 million U.S. children passed through the 0-5 age group;
consequently the incidence rate reported to VAERS was 0.10 KD cases per
100,000 person-years. (Pediatr Infect Dis J 28:943, 2009) From 1988 to
2006 the published KD incidence for U.S. children under 5 rose from 11.0
to
20.8 per 100,000 person-years. (Pediatrics 111:448, 2003. Pediatrics
112:495, 2003. Pediatr Infect Dis J 29:483, 2010) Even for infants 3-6
months old, when suspicion for vaccine adverse effects should be
especially
high, KD incidence as reported to VAERS was 0.11 while published
background rates were 23.1 (2000) and 24.6 (2006); fewer than 1 in 200 KD
cases were reported to VAERS.
It is bewildering, therefore,
to learn
that FDA and CDC officials used VAERS data to dismiss a placebo-controlled
trial that found a 5-fold KD risk associated with RotaTeq--RR=4.9; 95% CI6/15/07.
) If confirmed by a larger trial, the KD
0.6, 239. (Pediatr Infect Dis J 28:943, 2009.
risk
associated with RotaTeq would translate to an extra 4000 U.S. cases
annually
in young children.
I know that this discussion began with
febrile
convulsions in young children given seasonal flu vaccine, but the problems
with voluntary reporting systems, underreporting of adverse events and the
way the data are used by public health officials and the vaccine industry
apply
to other vaccines and other serious clinical problems. How can public
health
officials rely on a system that reports fewer than 1% of adverse effects?
How
can they dismiss placebo-controlled trials that raise serious
possibilities of
vaccine-caused illness?
Competing interests:
None declared
Competing interests: No competing interests